Rhea-AI Summary
MorphoSys AG (FSE:MOR) and Incyte announced that Monjuvi (tafasitamab-cxix) is now included in the NCCN Guidelines for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with a Category 2A designation. This designation applies to adult patients who have previously received treatment and are ineligible for autologous stem cell transplant. Monjuvi, approved by the FDA on July 31, 2020, offers a much-needed option for patients with limited treatments. Approximately 10,000 patients in the U.S. are diagnosed annually with this condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
FAQ
What is the current stock price of MorphoSys (MOR)?
MorphoSys (MOR) last closed at $18.64.
What is the market cap of MorphoSys (MOR)?
The market cap of MorphoSys (MOR) is approximately $2.9B.